Post-Partum Depression Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major post-partum depression markets reached a value of US$ 4.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 50.2 Billion by 2034, exhibiting a growth rate (CAGR) of 24.68% during 2024-2034.
The post-partum depression market has been comprehensively analyzed in IMARC’s new report titled “Post-Partum Depression Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Post-partum depression is a complex mix of physical, emotional, and behavioral changes that usually occur within a few months to a year after childbirth. It is considered one of the primary reasons for both maternal suffering and ill health. Some significant causes associated with post-partum depression can be physiological, situational, or multifactorial. Several symptoms are associated with post-partum depression, including depressed mood or extreme mood swings, loss of appetite or eating more than usual, insomnia, overwhelming tiredness, intense irritability or anger, severe anxiety, panic attacks, etc. A specific test for the diagnosis of post-partum depression is yet to be invented. The healthcare provider usually evaluates the individual upon their post-partum visit to the hospital. As part of the evaluation, the healthcare provider may do a depression screening, including having to fill out a questionnaire. They may order additional tests to rule out other causes for the symptoms if needed. Moreover, an Edinburgh Postnatal Depression Scale test can also be used to diagnose post-partum depression.
The rising incidences of mood disorders and anxiety on account of the increasing imbalance of hormones during and after pregnancy are primarily driving the post-partum depression market. In addition to this, the growing prevalence of associated risk factors, such as pregnancy-related physical changes, constant sleep deprivation, loneliness, complicated or difficult labor, low levels of social support, etc., is also bolstering the market growth. Moreover, the inflating awareness about mental health among the masses coupled with the increasing number of support groups and communities for new mothers is further creating a positive outlook for the global market. Besides this, the rising number of initiatives to treat post-partum depression through telemedicine virtual assistance over calls and online counseling are also propelling the global market. Additionally, the emerging popularity of various post-partum depression management approaches that involve healthy lifestyle choices, avoiding isolation, shared responsibilities between both parents, etc., is further acting as a significant growth-inducing factor. Apart from this, the escalating number of ongoing clinical trials for evaluating the efficacy and therapeutic potential of new drugs to treat post-partum depression is also augmenting the market growth. Numerous other factors, such as the widespread adoption of combination therapies and the growing usage of selective serotonin reuptake inhibitors owing to their high level of effectiveness and general safety, are expected to drive the post-partum depression market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the post-partum depression market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for post-partum depression and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post-partum depression market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the post-partum depression market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the post-partum depression market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current post-partum depression marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the post-partum depression market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the post-partum depression market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the post-partum depression market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the post-partum depression patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of post-partum depression?
What will be the growth rate of patients across the seven major markets?
Post-Partum Depression: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for post-partum depression drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post-partum depression market?
The post-partum depression market has been comprehensively analyzed in IMARC’s new report titled “Post-Partum Depression Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Post-partum depression is a complex mix of physical, emotional, and behavioral changes that usually occur within a few months to a year after childbirth. It is considered one of the primary reasons for both maternal suffering and ill health. Some significant causes associated with post-partum depression can be physiological, situational, or multifactorial. Several symptoms are associated with post-partum depression, including depressed mood or extreme mood swings, loss of appetite or eating more than usual, insomnia, overwhelming tiredness, intense irritability or anger, severe anxiety, panic attacks, etc. A specific test for the diagnosis of post-partum depression is yet to be invented. The healthcare provider usually evaluates the individual upon their post-partum visit to the hospital. As part of the evaluation, the healthcare provider may do a depression screening, including having to fill out a questionnaire. They may order additional tests to rule out other causes for the symptoms if needed. Moreover, an Edinburgh Postnatal Depression Scale test can also be used to diagnose post-partum depression.
The rising incidences of mood disorders and anxiety on account of the increasing imbalance of hormones during and after pregnancy are primarily driving the post-partum depression market. In addition to this, the growing prevalence of associated risk factors, such as pregnancy-related physical changes, constant sleep deprivation, loneliness, complicated or difficult labor, low levels of social support, etc., is also bolstering the market growth. Moreover, the inflating awareness about mental health among the masses coupled with the increasing number of support groups and communities for new mothers is further creating a positive outlook for the global market. Besides this, the rising number of initiatives to treat post-partum depression through telemedicine virtual assistance over calls and online counseling are also propelling the global market. Additionally, the emerging popularity of various post-partum depression management approaches that involve healthy lifestyle choices, avoiding isolation, shared responsibilities between both parents, etc., is further acting as a significant growth-inducing factor. Apart from this, the escalating number of ongoing clinical trials for evaluating the efficacy and therapeutic potential of new drugs to treat post-partum depression is also augmenting the market growth. Numerous other factors, such as the widespread adoption of combination therapies and the growing usage of selective serotonin reuptake inhibitors owing to their high level of effectiveness and general safety, are expected to drive the post-partum depression market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the post-partum depression market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for post-partum depression and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post-partum depression market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the post-partum depression market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the post-partum depression market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current post-partum depression marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the post-partum depression market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the post-partum depression market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the post-partum depression market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the post-partum depression patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of post-partum depression?
What will be the growth rate of patients across the seven major markets?
Post-Partum Depression: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for post-partum depression drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post-partum depression market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POST-PARTUM DEPRESSION - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (2024-2034?)
4.4 Competitive Intelligence
5 POST-PARTUM DEPRESSION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POST-PARTUM DEPRESSION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
8 POST-PARTUM DEPRESSION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POST-PARTUM DEPRESSION - UNMET NEEDS
10 POST-PARTUM DEPRESSION - KEY ENDPOINTS OF TREATMENT
11 POST-PARTUM DEPRESSION - MARKETED PRODUCTS
11.1 List of Post-partum Depression Marketed Drugs Across the Top 7 Markets
11.1.1 Zulresso (brexanolone) - Sage Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 POST-PARTUM DEPRESSION - PIPELINE DRUGS
12.1 List of Post-partum Depression Pipeline Drugs Across the Top 7 Markets
12.1.1 5 Methoxy N N dimethyltryptamine - GH Research
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BRII 296 - Brii Biosciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Zuranolone - SAGE Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. POST-PARTUM DEPRESSION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 POST-PARTUM DEPRESSION - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Post-Partum Depression - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034?)
14.2.2 Post-Partum Depression - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034?)
14.3 Market Scenario - United States
14.3.1 Post-Partum Depression - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034?)
14.3.2 Post-Partum Depression - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034?)
14.3.3 Post-Partum Depression - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Post-Partum Depression - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034?)
14.4.2 Post-Partum Depression - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034?)
14.4.3 Post-Partum Depression - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Post-Partum Depression - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034?)
14.5.2 Post-Partum Depression - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034?)
14.5.3 Post-Partum Depression - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Post-Partum Depression - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034?)
14.6.2 Post-Partum Depression - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034?)
14.6.3 Post-Partum Depression - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Post-Partum Depression - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034?)
14.7.2 Post-Partum Depression - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034?)
14.7.3 Post-Partum Depression - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Post-Partum Depression - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034?)
14.8.2 Post-Partum Depression - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034?)
14.8.3 Post-Partum Depression - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Post-Partum Depression - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034?)
14.9.2 Post-Partum Depression - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034?)
14.9.3 Post-Partum Depression - Access and Reimbursement Overview
15 POST-PARTUM DEPRESSION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 POST-PARTUM DEPRESSION MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POST-PARTUM DEPRESSION - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (2024-2034?)
4.4 Competitive Intelligence
5 POST-PARTUM DEPRESSION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POST-PARTUM DEPRESSION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
8 POST-PARTUM DEPRESSION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POST-PARTUM DEPRESSION - UNMET NEEDS
10 POST-PARTUM DEPRESSION - KEY ENDPOINTS OF TREATMENT
11 POST-PARTUM DEPRESSION - MARKETED PRODUCTS
11.1 List of Post-partum Depression Marketed Drugs Across the Top 7 Markets
11.1.1 Zulresso (brexanolone) - Sage Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 POST-PARTUM DEPRESSION - PIPELINE DRUGS
12.1 List of Post-partum Depression Pipeline Drugs Across the Top 7 Markets
12.1.1 5 Methoxy N N dimethyltryptamine - GH Research
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BRII 296 - Brii Biosciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Zuranolone - SAGE Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. POST-PARTUM DEPRESSION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 POST-PARTUM DEPRESSION - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Post-Partum Depression - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034?)
14.2.2 Post-Partum Depression - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034?)
14.3 Market Scenario - United States
14.3.1 Post-Partum Depression - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034?)
14.3.2 Post-Partum Depression - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034?)
14.3.3 Post-Partum Depression - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Post-Partum Depression - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034?)
14.4.2 Post-Partum Depression - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034?)
14.4.3 Post-Partum Depression - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Post-Partum Depression - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034?)
14.5.2 Post-Partum Depression - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034?)
14.5.3 Post-Partum Depression - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Post-Partum Depression - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034?)
14.6.2 Post-Partum Depression - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034?)
14.6.3 Post-Partum Depression - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Post-Partum Depression - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034?)
14.7.2 Post-Partum Depression - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034?)
14.7.3 Post-Partum Depression - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Post-Partum Depression - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034?)
14.8.2 Post-Partum Depression - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034?)
14.8.3 Post-Partum Depression - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Post-Partum Depression - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034?)
14.9.2 Post-Partum Depression - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034?)
14.9.3 Post-Partum Depression - Access and Reimbursement Overview
15 POST-PARTUM DEPRESSION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 POST-PARTUM DEPRESSION MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
